基蛋生物(603387) - 2024 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2024 was CNY 321,582,715.19, representing a decrease of 16.32% compared to the same period last year[5]. - The net profit attributable to shareholders was CNY 86,013,453.60, down 29.22% year-on-year[5]. - The net profit after deducting non-recurring gains and losses was CNY 82,736,693.46, a decrease of 17.71% compared to the previous year[5]. - The basic and diluted earnings per share were both CNY 0.17, reflecting a decline of 29.17% year-on-year[5]. - Total operating revenue for Q1 2024 was ¥321,582,715.19, a decrease of 16.3% compared to ¥384,316,306.14 in Q1 2023[25]. - Net profit for Q1 2024 was ¥87,436,875.95, down 29.7% from ¥124,371,119.11 in Q1 2023[26]. - Basic and diluted earnings per share for Q1 2024 were both ¥0.17, compared to ¥0.24 in Q1 2023[27]. Cash Flow - The net cash flow from operating activities increased significantly by 397.71%, amounting to CNY 67,114,506.07[5][10]. - Cash flow from operating activities generated a net inflow of ¥67,114,506.07, significantly up from ¥13,484,563.45 in the same period last year[30]. - Cash flow from investing activities resulted in a net outflow of ¥100,419,774.08, compared to a net inflow of ¥103,596,691.92 in Q1 2023[30]. - Cash flow from financing activities showed a net outflow of ¥32,994,084.94, worsening from a net outflow of ¥26,790,759.52 in Q1 2023[30]. - The net increase in cash and cash equivalents for Q1 2024 was -$65,889,106.33, compared to an increase of $88,332,104.53 in the same period last year[31]. - The ending balance of cash and cash equivalents for Q1 2024 was $417,286,545.60, down from $732,976,882.93 in the previous year[31]. - The beginning balance of cash and cash equivalents was $483,175,651.93, indicating a decrease in available cash[31]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 3,788,151,087.27, a slight increase of 0.44% from the end of the previous year[6]. - Total current assets as of March 31, 2024, amounted to CNY 2,021.27 million, down from CNY 2,151.18 million at the end of 2023[21]. - Total liabilities decreased from CNY 1,030.38 million at the end of 2023 to CNY 963.62 million as of March 31, 2024[22]. - The company's total assets as of March 31, 2024, were CNY 3,788.15 million, slightly up from CNY 3,771.63 million at the end of 2023[21]. - Shareholders' equity attributable to the parent company increased by 3.39% to CNY 2,646,087,081.99[6]. Operational Highlights - In Q1 2024, the company's self-produced products generated revenue of CNY 260.60 million, a year-on-year decrease of 6.56% due to last year's high base[17]. - The core product Getein1600 shipped over 130 units in Q1, maintaining the company's leading position in the POCT field[17]. - The small luminescence products (MAGICL6000 + MAGICL6000i) saw a shipment of over 220 units in Q1, with MAGICL6000i accounting for nearly 90 units, resulting in a revenue increase of 58.42% for the chemiluminescence line, totaling CNY 68.41 million[17]. - The Metis6000 fully automated immunoassay production line was launched in Q1 2023, with nearly 30 units installed in Q1 2024, bringing the total to nearly 100 units, over 50% of which are in secondary hospitals[18]. - The company continues to focus on regular business operations and market expansion while enhancing cost control and efficiency[17]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 30,655[12]. - The company has not reported any changes in the borrowing or lending of shares among major shareholders during the reporting period[16]. Expenses - Total operating costs decreased by 16.3% to ¥220,695,492.33 from ¥263,733,676.37 year-over-year[25]. - Research and development expenses decreased to ¥44,003,300.95, down 20.2% from ¥55,164,547.70 year-over-year[25]. - Sales expenses slightly decreased to ¥66,563,839.18 from ¥68,703,246.56 in Q1 2023[25]. - The company reported a significant increase in other income to ¥6,877,977.00 from ¥11,258,800.02 in the previous year[25]. Return on Equity - The weighted average return on equity decreased by 1.48 percentage points to 3.30%[6].